Todos Medical aims to develop and bring to market its revolutionary blood tests for detecting biomarkers of cancer (lat. Carcinoma). The company is spinoff of Ben-Gurion University (BGUni). Their new cancer test will add a layer to currently available cancer screening and diagnostics. The goal is to help save lives through early detection while being minimally invasive to the patient. Todos Medical’s vision is to become the standard of care in the way people are routinely checked for cancer (early detection). The new method is easy to implement and at a low cost, currently targeting the mass population as the first choice for cancer detection. The technology is a platform, and scientists are investigating methods for using the platform on other types of cancers. As a start scientists are focused on breast and colon cancers.
Screening tests for cancer in general and breast, colon, lung cancers specifically have well-known limitations and compliance shortcomings due to their scientific limitations, invasive procedures, and expensive nature of more accurate diagnostic methods. More importantly, many of the most effective diagnostic methods remain too expensive for adoption as screening tests for all those at risk and are used too rarely and too late stage to allow for the most effective treatment. Blood-based tests are the future of cancer screening. Todos Medical’s TBIA platform represents a cost-effective, scalable, and patient-friendly screening method for cancer screening.
Todos Medical has developed the 'Total Biochemical Infrared Analysis' (TBIA) method, a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence rather than looking for the tumor cells themselves or specific markers. TBIA analyzes the entire biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of affected immune cells from peripheral blood, using infrared spectroscopy.
Their breast cancer blood Test is targeting a large population of women that need to be checked regularly for breast cancer, whether that is because of a high-risk group or at an age that women are routinely screened. Usually, all women above 40 years old undergo breast testing. The recommended testing protocol using Mammography and Ultrasound have their limitations and discomfort. Their proprietary TM-B1 cancer test will support current cancer diagnostic protocols in their weak points (like dense breast tissue and young woman) and give a simple and low-cost solution for early detection. Their proprietary TM-B2 cancer screen will allow health care providers to distinguish between benign and malignant breast tumors. Todos Medical has collected over 1,000 clinical samples in several clinical trials for breast and other cancers at the Wolfson Medical Center (Holon, Israel), Rabin Medical Center (Petach Tikva, Israel), Ichilov Medical center (Tel Aviv, Israel) and in Ukraine. The latest clinical trial for Todos Medical’s breast cancer test included 59 patients and achieved 93% sensitivity and 87% specificity as compared to routine mammography screening.
Colonoscopy is the current standard in Colorectal Cancer (CRC) testing. Their proprietary TM-C1 cancer test is targeting the detection of colorectal cancers at an early stage. A large percentage of patients (40% or higher) who have been recommended to undergo a colonoscopy do not get one (mainly due to discomfort and cost). Their TM-C1 test is a groundbreaking cancer test that will indicate the presence of colon cancer. As it is a blood test, it is minimally invasive and affordable. If colon cancer is detected, the physician can then determine appropriate next steps. TM-C1 is not intended to replace colonoscopies or other standard diagnostic methods. Their goal is to incorporate TM-C1 test into the current colon cancer screening protocols in order to save lives by improving early detection. Todos Medical has collected over 1,000 clinical samples in several clinical trials for breast and other cancers at the Wolfson Medical Center (Holon, Israel), Rabin Medical Center (Petach Tikva, Israel), Ichilov Medical center (Tel Aviv, Israel) and in the Ukraine. The latest clinical trial (link to article in publication section) for Todos Medical’s colorectal cancer test included 64 patients and achieved 82% sensitivity and 91% specificy as compared to colonoscopy screening.